Cyclacel pharmaceuticals highlights preclinical data showing that cancer of the biliary tract is sensitive to plogosertib

- biliary tract cancer (btc) or cholangiocarcinoma is an aggressive tumor with poor prognosis - kuala lumpur, malaysia, aug. 04, 2025 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, “ evaluation of antitumor effects of plogosertib, plk1 inhibitor in biliary tract cancer with bubr1 as a potential biomarker ” in the journal, cancer research, previously reported in a poster at the american association of cancer research 2025 annual meeting.1 the investigators found that several btc cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (mcc) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of btc cells.
CYCC Ratings Summary
CYCC Quant Ranking